Dasatinib News and Research

RSS

Dasatinib is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.

Novel Activation Mechanism for First Identified Oncogene

In the late 1970s, the link between the c-Src gene and cancer was unveiled, marking the identification of the inaugural oncogene.

1 Nov 2023

MET+LEU Cocktail Prevents Cellular Senescence and Disrupted Proteostasis Induced by Myotube Atrophy

A new research paper was published on the cover of Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 15, Issue 6, entitled, "Cellular senescence and disrupted proteostasis induced by myotube atrophy are prevented with low-dose metformin and leucine cocktail."

3 Apr 2023

Study pinpoints a key cause of metastasis from an aggressive form of pediatric brain cancer

New research pinpoints a key cause of metastasis from an aggressive form of brain cancer in children and provides a potential new therapy for treating these tumors in the future.

7 Mar 2023